RE: Best Case Scenario Well this latest news should give you an idea. Looks promising :)
PharmaGap Inc. has provided an update on the current developmental status of its lead drug program.
Animal studies completed in January, 2012, tested the PharmaGap drug formulations in head-to-head comparisons against Carboplatin using ovarian cancer cell lines OCC-1, A2780cp and ES-2 implanted into mouse subjects. These tests indicated GAP-107B8 reduced malignant ascites up to 88 per cent compared with the Carboplatin control at 42 per cent. Tumour burden was reduced by 62% in the OCC-1 model using GAP-107B8 compared with Carboplatin control at 72% reduction. The company expects that future test protocols in animals with refined dosing schedules can improve on these results.